Sensus Healthcare (SRTS) to Release Earnings on Thursday

Sensus Healthcare (NASDAQ:SRTS) is projected to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.1250) per share and revenue of $4.6010 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.04). Sensus Healthcare had a negative net margin of 34.50% and a negative return on equity of 15.79%. The company had revenue of $3.39 million during the quarter, compared to analysts’ expectations of $5.32 million.

Sensus Healthcare Trading Down 3.1%

SRTS stock opened at $2.85 on Thursday. The stock has a market cap of $46.91 million, a P/E ratio of -6.06 and a beta of 1.09. Sensus Healthcare has a twelve month low of $2.66 and a twelve month high of $5.92. The company’s 50 day moving average is $2.95 and its two-hundred day moving average is $3.81.

Institutional Investors Weigh In On Sensus Healthcare

Several large investors have recently modified their holdings of the company. XTX Topco Ltd acquired a new position in shares of Sensus Healthcare in the 4th quarter valued at $77,000. Jane Street Group LLC purchased a new stake in Sensus Healthcare in the 4th quarter valued at $79,000. Geode Capital Management LLC boosted its stake in Sensus Healthcare by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 158,240 shares of the company’s stock worth $630,000 after purchasing an additional 5,316 shares during the period. Greenline Wealth Management LLC purchased a new position in Sensus Healthcare during the 4th quarter worth $513,000. Finally, Rothschild Wealth LLC acquired a new position in Sensus Healthcare in the fourth quarter valued at $500,000. 25.30% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently commented on SRTS shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research report on Friday, July 17th. Wall Street Zen cut shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Finally, Citigroup restated a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $6.88.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.